Ergogenic effects of pseudoephedrine on edurance performance in relation to the determination of threshold values in urine and capillary and venous blood

Conditions

Healthy volunteers

Brief summary

Change in time trial duration (and average power output) when the placebo trial (0 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine

Detailed description

Changes in physiological parameters (cardiovascular, oxidative and metabolic) during the 90’ long cycling race simulation when the placebo trial (0 mg) is compared to the trial with ingestion of 120 mg Pseudoephedrine, Changes in physiological parameters (cardiovascular, oxidative and metabolic) during the 90’ long cycling race simulation when the placebo trial (0 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine, The upper limit of the 95% CI of the mean maximal measured blood/urine pseudoephedrine concentration after ingestion of 240 mg of pseudoephedrine for each sampling method (TASSO+, VAMS, DBS, Venapuncture and urine collection), Change in time trial duration (and average power output) when the half-dose trial (120 mg) is compared to the trial with ingestion of 0 mg Pseudoephedrine., Change in time trial duration (and average power output) when the half-dose trial (120 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine.

Related papers

No related papers found yet.

Papers published before 2007-09-01 may not appear yet. Historical indexing is in progress.

Interventions

DRUGP-Tabletten weiß 7 mm Lichtenstein

DRUGVasocedine pseudoephedrine 60 mg

DRUGfilmomhulde tabletten

Eligibility

Sex/Gender

All

Age

18 Years to 64 Years

Design outcomes

Primary

Measure	Time frame
Change in time trial duration (and average power output) when the placebo trial (0 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine	—

Secondary

Measure	Time frame
Changes in physiological parameters (cardiovascular, oxidative and metabolic) during the 90’ long cycling race simulation when the placebo trial (0 mg) is compared to the trial with ingestion of 120 mg Pseudoephedrine, Changes in physiological parameters (cardiovascular, oxidative and metabolic) during the 90’ long cycling race simulation when the placebo trial (0 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine, The upper limit of the 95% CI of the mean maximal measured blood/urine pseudoephedrine concentration after ingestion of 240 mg of pseudoephedrine for each sampling method (TASSO+, VAMS, DBS, Venapuncture and urine collection), Change in time trial duration (and average power output) when the half-dose trial (120 mg) is compared to the trial with ingestion of 0 mg Pseudoephedrine., Change in time trial duration (and average power output) when the half-dose trial (120 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine.	—

Measure

Time frame

Changes in physiological parameters (cardiovascular, oxidative and metabolic) during the 90’ long cycling race simulation when the placebo trial (0 mg) is compared to the trial with ingestion of 120 mg Pseudoephedrine, Changes in physiological parameters (cardiovascular, oxidative and metabolic) during the 90’ long cycling race simulation when the placebo trial (0 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine, The upper limit of the 95% CI of the mean maximal measured blood/urine pseudoephedrine concentration after ingestion of 240 mg of pseudoephedrine for each sampling method (TASSO+, VAMS, DBS, Venapuncture and urine collection), Change in time trial duration (and average power output) when the half-dose trial (120 mg) is compared to the trial with ingestion of 0 mg Pseudoephedrine., Change in time trial duration (and average power output) when the half-dose trial (120 mg) is compared to the trial with ingestion of 240 mg Pseudoephedrine.

—

Countries

Belgium

Outcome results

None listed